 |
Dr. Jin Li, Chairman and CEO of HitGen:
“As an innovative biopharmaceutical company dedicated to ‘contributing to human health,’ HitGen has always believed that the core of an enterprise lies in continuously creating value. In 2025, we remained pragmatic and steadfast, integrating sustainable development into our strategy, management, and operations, laying a solid foundation for enduring success. In practice, we continue to contribute our modest efforts to customers, partners, investors, employees, and the environment and communities we rely on.”
- Sustainable Governance
HitGen continuously optimizes its governance system, upholds integrity in business operations to set industry benchmarks, and establishes a comprehensive risk management framework. This drives the company’s long-term and stable development, creating sustainable value for all stakeholders.
- Responsible Value Chain
HitGen adheres to product safety and service quality, builds a sustainable supply chain, and systematically manages all aspects of the value chain. The company is committed to collaborating with stakeholders to create long-term, comprehensive value.
- Employees and Community
HitGen regards employees as the core driving force of sustainable development and the community as an important partner for mutual growth. The company upholds a people-oriented philosophy and a sense of social responsibility, fostering employee development and community progress together.
- Environmental Management
HitGen adheres to a green development philosophy, integrating environmental management into its operations and development strategy. The company systematically advances efforts in environmental management and ecological protection, waste management, resource utilization, and climate change response.
Dr. Jin Li stated: “A journey of a thousand miles begins with a single step. On the path to becoming a world-class innovative biopharmaceutical company, we will continue to adhere to market demand as our guide and technological breakthroughs as our engine, continuously optimizing our innovative drug R&D service system to contribute to building a more inclusive, healthy, green, and inclusive world.”
To view the full HitGen 2025 Sustainability Report, please visit the link: https://www.hitgen.com/cn/sustainability.html
About HitGen
HitGen Inc. (Stock Code: 688222.SH) is committed to becoming a globally influential innovative biopharmaceutical enterprise, providing innovative treatment solutions to address unmet clinical needs and contributing to the improvement of human health and quality of life. The company is centered on its world-leading DEL (DNA-encoded compound library) technology, and has expanded into fragment-based and three-dimensional structure-based drug design, as well as oligonucleotide-based drug R&D technology, proximity-induced drug R&D technology, and macrocyclic peptide derivative technology platforms. It has also independently developed the “DEL+AI+Automation” integrated molecular optimization platform HAILO, establishing a unique new molecule discovery system that provides therapeutic molecules and novel tool molecules to the global pharmaceutical industry. Headquartered in Chengdu, China, HitGen has subsidiaries in Cambridge, UK, and Houston, USA, with a business network spanning the globe. Through business models including new drug R&D services, transfer of projects at various stages, and future drug commercialization, HitGen has established extensive collaborations with numerous pharmaceutical companies, biotechnology companies, chemical companies, foundations, and research institutions worldwide. As of the end of 2025, the company has empowered over 600 clients globally with thousands of innovative drug R&D projects. HitGen has multiple internal new drug projects at various stages of clinical and preclinical development. For more information, please visit www.hitgen.com.